Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10003425.5Aexternal-prioritypatent/EP2218448B1/en
Application filed by Durect CorporationfiledCriticalDurect Corporation
Publication of CY1117091T1publicationCriticalpatent/CY1117091T1/en
Μια από του στόματος λαμβανόμενη φαρμακοτεχνική μορφή που περιλαμβάνει ένα σκεύασμα το οποίο περιλαμβάνει ένα υγρό φέρον υλικό υψηλούς ιξώδους (HVLCM), έναν παράγοντα σχηματισμού δικτύου και ένα φάρμακο. To HVLCM είναι συνήθως ισοβουτυρική οξική σακχαρόζη.An oral formulation comprising a formulation comprising a liquid high viscosity carrier material (HVLCM), a network forming agent and a medicament. HVLCM is usually sucrose isobutyrate acetate.
CY20151101067T2002-12-132015-11-26
ORAL SYSTEM FOR ADMINISTRATION OF MEDICINAL PRODUCT INCLUDING LIQUID CARE OF HIGH Viscosity Materials
CY1117091T1
(en)
A DRUG FORMULATION FOR ORAL ADMINISTRATION OF CONTROLLED PELLET PELLET THAT HAS CONTROLLED RELEASE OF AN ACTIVE COMPOUND THAT IS SELECTED FROM THE ACID 1-CYCLOPROPIL-7- [(S, S) -2,8-DIAZABICICLO [4.3.0] NON- 8-IL] -6-FLUOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-CARBOXILIC QUINOLON OR SALE